fidaxomicin (dificid) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fidaxomicin (trade names Dificid, Dificlir in Europe) is the first in a new class of narrow spectrum macrocyclic antibiotic drugs indicated for treatment of Clostridium difficile-associated diarrhea. Lipiarmycin (fidaxomicin), a metabolite of Actinoplanes deccanensis nov. sp. was first isolated in pure form in 1970s and was considered as antibiotic from its chemical and physico-chemical characteristics. It demonstrated high activity against Gram-positive bacteria, including strains resistant to the medically important antibiotics and protected mice experimentally infected with Streptococcus haemolyticus. Fidaxomicin is non-systemic, meaning it is minimally absorbed into the bloodstream, it is bactericidal, and it has demonstrated selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora. Although the exact mechanism of action has yet to be fully elucidated, fidaxomicin may bind to and inhibit bacterial DNA-dependent RNA polymerase, thereby inhibiting the initiation of bacterial RNA synthesis. When orally administered, this agent is minimally absorbed into the systemic circulation, acting locally in the gastrointestinal tract. Fidaxomicin appears to be active against pathogenic Gram-positive bacteria, such as clostridia, enterococci, and staphylococci, but does not appear to be active against other beneficial intestinal bacteria. The maintenance of normal physiological conditions in the colon can reduce the probability of Clostridium difficile infection recurrence. It is marketed by Cubist Pharmaceuticals after acquisition of its originating company Optimer Pharmaceuticals.   NCATS

Chemistry

  • SMILES: CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)C3=C(O)C(Cl)=C(O)C(Cl)=C3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(C)\C=C(C)\[C@@H]1O[C@@H]4OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]4O)[C@@H](C)O
  • InChIKey: ZVGNESXIJDCBKN-UUEYKCAUSA-N
  • Mol. Mass: 1058.039
  • ALogP: Missing data
  • ChEMBL Molecules:
    fidaxomicin  
    lipiarmycin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$123.7840 - $3022.9800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

dificid | dificlir | difimicin | fidaxomicin | fidazomicin | lipiarmicin | lipiarmycin | lipiarmycin a3 | lipiarmycin a4 | lipiarmycin b | lipiarmycin b3 | lipiarmycin b4 | lipiarrmycin | opt 80 | opt-80 | opt80 cpd | par101 | par 101 | par-101 | tiacumicin b | tiacumicin c | tiawmicin b

Organizations (26)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Diarrhea

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Clostridioides difficile (Phase 4)

Clostridium (Phase 4)

Clostridium Infections (Phase 4)

Diarrhea ()

Drug Interactions (Phase 1)

Enterocolitis (Phase 4)

Fidaxomicin (Phase 4)

Healthy Volunteers (Phase 1)

Infections (Phase 3)

Inflammatory Bowel Diseases (Phase 4)

Intestinal Absorption (Phase 1)

Organ Transplantation (Phase 4)

Pharmacokinetics (Phase 1)

Spinal Cord Injuries (Phase 4)

Vancomycin (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue